Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIMBER-313
jRCT2071200114Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Jul 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more comparing parsaclisib + ruxolitinib with placebo + ruxolitinib (2 arms). Primary endpoint: Proportion of participants achieving targeted reduction in spleen volume. Started Jul 2021; status: active, not recruiting.
02
Drugs
parsaclisibruxolitinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on jRCT2071200114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200114.